Answers are grounded in this paper and cite their sources.
Sarcopenia involves declines in muscle mass, muscle strength, and physical function. Identifying effector genes, their favourable expression directions, and broader phenotypic associations from genome-wide association study (GWAS) signals remains challenging. We integrated GWAS summary statistics for hand grip strength (HGS) and appendicular lean mass (ALM) with H3K27ac annotation, AlphaGenome variant effect predictions, and skeletal muscle expression data. We then applied cis-eQTL Mendelian randomization (MR) and colocalization across HGS, ALM, low hand grip strength (LHGS), and usual walking pace. Across 59 HGS–ALM cross-trait candidate regions, AlphaGenome predicted 2288 regulatory variants among 16,245 candidate enhancer SNPs and nominated 135 protein-coding effector genes. Four-trait MR identified 30 genes with significant causal effects, including 13 with concordant effect directions across multiple traits. FGF6, CCND2, and HOXB3 also received strong colocalization support. Phenome-wide MR across 784 UK Biobank disease phenotypes revealed distinct benefit–risk profiles for 7 genes. Higher CCND2 expression improved sarcopenia-related traits and reduced type 2 diabetes risk but increased the risks of parathyroid disease and atrial fibrillation and flutter. Higher HOXB3 expression increased HGS and reduced the risks of LHGS and diverticular disease. Lower FGF6 expression increased ALM, with no risk-increasing effect detected. This workflow prioritizes skeletal muscle effector genes and their favourable expression directions for sarcopenia-related traits to guide functional validation and translation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: